New eye drops aim to heal damaged corneas

NCT ID NCT07568730

Recruiting now Symptom relief Sponsor: TearSolutions, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial tests Lacripep eye drops in 54 people with neurotrophic keratitis, a condition where the cornea loses feeling and can get damaged. The study compares the drops to a placebo to see if they safely improve eye surface health, vision, and quality of life over 8 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Lacripep eye drops
What this could lead to: If it works, this could point toward a treatment for neurotrophic keratitis, a rare eye disease that can lead to vision loss.
What could go wrong: This is an early Phase 2 trial with only 54 participants, so results may not apply to everyone. The eye drops may not improve symptoms or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROTROPHIC KERATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neurotrophic keratopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEUROTROPHIC KERATITIS

Contacts and locations

Show contact details

Locations

Midwest Cornea Associates
RECRUITING

Carmel, Indiana, 46032, United States

Contact Email: •••••@•••••
Minnesota Eye Consultants
RECRUITING

Minneapolis, Minnesota, 55431, United States
Ophthalmology Associates
NOT_YET_RECRUITING

St Louis, Missouri, 63131, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.